|
Product |
Generic Name |
MOA |
Manufacturer |
Indication |
Side Effects |
Dose |
Comments |
Recent Clinical trials |
|
Avonex |
interferon beta-1a |
slows growth of white blood cells |
Biogen Idec |
RRMS (relapsing forms of M.S.) |
Flu-like symptoms, injection site reactions, monitoring of blood cell counts and
liver function |
IM, 1X week, 30 mcg |
Convenient dosing |
1.
Avonex (Interferon-Beta-1a) and Avonex Plus Methylprednisolone for the Treatment
of Relapsing-Remitting MS, 2003-2008 (NCT00168766) |
Betaseron
|
interferon beta-1b |
slows growth of white blood cells |
Bayer/Berlex/Schering
|
RRMS (relapsing forms of M.S.) |
Flu-like symptoms, injection site reactions, monitoring of blood cell counts and
liver function |
Subq, every other day, 250 mcg |
High dose
|
1.
Safety Study in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Receiving
Betaferon or Rebif, 2006-2007 (NCT00317941)
2.
RNF and Betaseron® Tolerability Study (REFORMS), 2006-2008 (NCT00428584) 3.
BEYOND - Betaferon/Betaseron Efficacy Yielding
Outcomes of a New Dose, 2003-? (NCT00099502) also compared to copaxone
|
|
Rebif |
interferon beta-1a |
slows growth of white blood cells |
Merck Serono |
RRMS (relapsing forms of M.S.) |
Flu-like symptoms, injection site reactions, monitoring of blood cell counts and
liver function |
Subq, 3X week, 44 mcg |
Most efficacious DMT against RRMS |
1.
REGARD - Rebif® Versus Copaxone® in the
Treatment of Relapsing Remitting Multiple Sclerosis, 2004-2007 (NCT00078338) 2. Rebif New Formulation (RNF) Quality of Life Study (RebiQoL), 2007-2008
(NCT00472797)
2. Combination Therapy
Using Cellcept and Rebif in RRMS, 2006-2009 (NCT00618527) |
|
Copaxone |
glatiramer acetate |
Myelin decoy |
Teva/Sanofi |
RRMS |
Injection site reactions |
Subq, daily, 20 mg |
Interferon alternative, benign side effects |
1.
Treatment of MS with copaxone and albuterol (NCT00039988)
2. Clinical Trial Comparing Treatment of Relapsing-Remitting
Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA), 2006-2009
(NCT00337779) |
|
Novantrone |
mitoxantrone |
Topoisomerase II inhibitor, suppresses T-cells, B-cells, an d macrophages |
Serono |
Worsening RRMS and chronic progressive MS, not for primary progressive MS |
Cardiac toxicity |
IV, 4X/year (limit of 8-12 doses), 12 mg/m2 |
For progressive disease, preferred add-on therapy |
1.
Prospective, Open-Label Tolerability and Safety Monitoring Study of Novantrone
in a Selected Cohort of Multiple Sclerosis Patients, 2000-2008 (NCT00262314) |
Tysabri
|
natalizumab |
Anti-α4-subunit of
α4β1
and α4β7 integrins expressed on all leukocytes except neutrophils.
Selectively inhibits immune cells from leaving the bloodstream, prevents
migration into chronically inflamed tissues |
Biogen Idec/Elan |
RRMS (relapsing forms of M.S.) |
Hypersensitivity
|
15 ml dose containing 300 mg should be diluted with 100 ml of diluent and infused
by IV over approximately 1 hour
every four weeks.
Should not be administered as an IV push or bolus injection
|
Re-introduced in mid 2006, appears to be very effective, market could double from
today's level if long term safety looks good |
1. IMA-06-02 Tysabri
Observational Program, 2007-2012 (NCT00493298)
2. Natalizumab Re-Initiation of Dosing, 2006-2013
(NCT00297232)
3.
Natalizumab Re-Initiation of Dosing, 2006-2008 (NCT00306592)
4. Safety Study of Natalizumab to Treat Multiple
Sclerosis, 2007-2009 (NCT00559702)
5.
TYSABRI® Global Observational Program in Safety (TYGRIS), 2007-2014 (NCT00477113) 6. TYGRIS - ROW: TYSABRI®
Global Observational Program in Safety - Rest of World, 2006-2013 (NCT00483847)
|